Real-World calquence study tracks side effects in Tough-to-Treat leukemia
NCT ID NCT04872621
First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 28 times
Summary
This study looked at side effects of the drug Calquence (acalabrutinib) in 104 people with relapsed or refractory chronic lymphocytic leukemia (a type of blood cancer that has come back or not responded to treatment). Researchers tracked real-world use to see how often problems like bleeding, infection, heart issues, or other serious side effects occurred. The goal was to better understand the drug's safety in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Aichi, D8224C00001, Japan
-
Research Site
Aichi, Japan
-
Research Site
Akita, Japan
-
Research Site
Aomori, D8224C00001, Japan
-
Research Site
Chiba, D8224C00001, Japan
-
Research Site
Chiba, Japan
-
Research Site
Fukui, Japan
-
Research Site
Fukuoka, D8224C00001, Japan
-
Research Site
Fukuoka, Japan
-
Research Site
Gifu, Japan
-
Research Site
Gunma, D8224C00001, Japan
-
Research Site
Gunma, Japan
-
Research Site
Hiroshima, D8224C00001, Japan
-
Research Site
Hiroshima, Japan
-
Research Site
Hokkaido, D8224C00001, Japan
-
Research Site
Hokkaido, Japan
-
Research Site
Hyōgo, D8224C00001, Japan
-
Research Site
Hyōgo, Japan
-
Research Site
Ibaraki, D8224C00001, Japan
-
Research Site
Ibaraki, Japan
-
Research Site
Ishikawa, Japan
-
Research Site
Kagoshima, D8224C00001, Japan
-
Research Site
Kagoshima, Japan
-
Research Site
Kanagawa, D8224C00001, Japan
-
Research Site
Kanagawa, Japan
-
Research Site
Kochi, Japan
-
Research Site
Kumamoto, Japan
-
Research Site
Kyoto, D8224C00001, Japan
-
Research Site
Kyoto, Japan
-
Research Site
Mie, Japan
-
Research Site
Miyagi, D8224C00001, Japan
-
Research Site
Miyagi, Japan
-
Research Site
Miyazaki, Japan
-
Research Site
Nagano, Japan
-
Research Site
Nagasaki, D8224C00001, Japan
-
Research Site
Nagasaki, Japan
-
Research Site
Nara, Japan
-
Research Site
Niigata, Japan
-
Research Site
Numakunai, Japan
-
Research Site
Okayama, Japan
-
Research Site
Okinawa, Japan
-
Research Site
Osaka, D8224C00001, Japan
-
Research Site
Osaka, Japan
-
Research Site
Ōita, Japan
-
Research Site
Saitama, D8224C00001, Japan
-
Research Site
Saitama, Japan
-
Research Site
Shiga, D8224C00001, Japan
-
Research Site
Shiga, Japan
-
Research Site
Shimane, Japan
-
Research Site
Shizuoka, D8224C00001, Japan
-
Research Site
Shizuoka, Japan
-
Research Site
Tokyo, D8224C00001, Japan
-
Research Site
Tokyo, Japan
-
Research Site
Tottori, Japan
-
Research Site
Toyama, Japan
-
Research Site
Wakayama, D8224C00001, Japan
-
Research Site
Wakayama, Japan
-
Research Site
Yamagata, Japan
-
Research Site
Yamaguchi, Japan
Conditions
Explore the condition pages connected to this study.